Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average (2016 - 2025)

China Pharma Holdings' Equity Average history spans 15 years, with the latest figure at $15.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 117.52% year-over-year to $15.5 million; the TTM value through Dec 2025 reached $15.5 million, up 117.52%, while the annual FY2025 figure was $15.2 million, 100.54% up from the prior year.
  • Equity Average reached $15.5 million in Q4 2025 per CPHI's latest filing, up from $7.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $15.5 million in Q4 2025 to a low of $3.4 million in Q3 2022.
  • Average Equity Average over 5 years is $6.6 million, with a median of $6.7 million recorded in 2023.
  • Peak YoY movement for Equity Average: crashed 48.73% in 2022, then surged 117.52% in 2025.
  • A 5-year view of Equity Average shows it stood at $6.4 million in 2021, then plummeted by 44.65% to $3.6 million in 2022, then skyrocketed by 90.39% to $6.8 million in 2023, then rose by 5.24% to $7.1 million in 2024, then surged by 117.52% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Equity Average are $15.5 million (Q4 2025), $7.4 million (Q3 2025), and $6.7 million (Q2 2025).